from wired.co.uk by by Liat Clark
A team of chemists has developed a new computational drug discovery technique that targets microRNAs using genome sequencing. To demonstrate the technique, which the research team believes presents a new and efficient, general-use approach to targeted drug discovery, they developed a drug that caused cancer cells to attack themselves.
“With our program, we can identify compounds with high specificity,” said Sai Pradeep Velagapudi, a graduate student at The Scripps Research Institute and lead author on a paper describing the technique, termed Inforna. “In the future, we hope we can design drug candidates for other cancers or for any pathological RNA.”
Typically, oligonucleotides have been used to target RNA and research tailored drugs. These are short nucleic acid polymers — single-stranded DNA or RNA molecules. Because they readily bind to their opposing nucleotide, they are often synthesised in the lab to use in detecting specific DNA or RNA. In 2012, CEO of RaNA Therapeutics Art Krieg called oligonucleotide therapeutics the “third major drug-development platform”, after small molecules and biologics. MicroRNAs have, in recent years, come to the fore though, and this latest technique has focused on the burst of innovation in the field and promises to aid better small molecule drug delivery. Only discovered in the 90s, they are short molecules, which function as gene controllers — they bind the genes to stop them becoming proteins.
[box type=”shadow” align=”alignleft” ]Velagapudi SP, Gallo SM, Disney MD. (2014)
Sequence-based design of bioactive small molecules that target precursor microRNAs.
Nat Chem Biol [Epub ahead of print]. [
abstract][/fusion_text][/fusion_builder_column_inner][/fusion_builder_row_inner][/fusion_builder_column]
from wired.co.uk by by Liat Clark
A team of chemists has developed a new computational drug discovery technique that targets microRNAs using genome sequencing. To demonstrate the technique, which the research team believes presents a new and efficient, general-use approach to targeted drug discovery, they developed a drug that caused cancer cells to attack themselves.
Typically, oligonucleotides have been used to target RNA and research tailored drugs. These are short nucleic acid polymers — single-stranded DNA or RNA molecules. Because they readily bind to their opposing nucleotide, they are often synthesised in the lab to use in detecting specific DNA or RNA. In 2012, CEO of RaNA Therapeutics Art Krieg called oligonucleotide therapeutics the “third major drug-development platform”, after small molecules and biologics. MicroRNAs have, in recent years, come to the fore though, and this latest technique has focused on the burst of innovation in the field and promises to aid better small molecule drug delivery. Only discovered in the 90s, they are short molecules, which function as gene controllers — they bind the genes to stop them becoming proteins.
[box type=”shadow” align=”alignleft” ]Velagapudi SP, Gallo SM, Disney MD. (2014) Sequence-based design of bioactive small molecules that target precursor microRNAs. Nat Chem Biol [Epub ahead of print]. [abstract][/fusion_text][/fusion_builder_column_inner][/fusion_builder_row_inner][/fusion_builder_column]Related Posts
Researchers create first whole-body single-cell atlas of an adult vertebrate
UAlbany Joins $10 Million Effort to Map RNA Modifications in the Human Body
Overlooked ‘off switch’ in lung tumors may explain why immunotherapy doesn’t work for everyone
Squids Edit RNA for Novel Protein Functions
New marker panel and web tool help define early human cell fates
Researchers Develop AI Tool to Map MicroRNA Binding Sites on Circular RNAs
“Raman Genome” for SARS-CoV-2: new Raman technology distinguishes viral variants by their molecular RNA architecture
Advanced paternal age has sex-specific effects on fetal brain gene expression
Exercise is good for us—but why?
Heart failure reshapes bone marrow to create inflammation-related immune memory
Overlooked DNA regions surrounding ‘microexons’ hold missing pieces of autism’s genetic puzzle
An anti-senescence gene may fight spinal disc deterioration
Scientists identify the neuroblastoma cells that signal poor outcomes
Urine test may improve bladder cancer diagnosis and guide treatment decisions
Tracing 700 million years of cell evolution
RNA-Seq reveals a new way the developing heart controls its growth
The Human RNome Project Consortium seeks to publish first-ever complete sequence of the body’s RNA
Unmasking “zombie cells” in aging tissue with an AI-powered barcode
RNA variant imaging for cancer diagnosis
Autism-risk mutations reveal two opposing patterns of brain gene activity
from wired.co.uk by by Liat Clark
A team of chemists has developed a new computational drug discovery technique that targets microRNAs using genome sequencing. To demonstrate the technique, which the research team believes presents a new and efficient, general-use approach to targeted drug discovery, they developed a drug that caused cancer cells to attack themselves.
Typically, oligonucleotides have been used to target RNA and research tailored drugs. These are short nucleic acid polymers — single-stranded DNA or RNA molecules. Because they readily bind to their opposing nucleotide, they are often synthesised in the lab to use in detecting specific DNA or RNA. In 2012, CEO of RaNA Therapeutics Art Krieg called oligonucleotide therapeutics the “third major drug-development platform”, after small molecules and biologics. MicroRNAs have, in recent years, come to the fore though, and this latest technique has focused on the burst of innovation in the field and promises to aid better small molecule drug delivery. Only discovered in the 90s, they are short molecules, which function as gene controllers — they bind the genes to stop them becoming proteins.
[box type=”shadow” align=”alignleft” ]Velagapudi SP, Gallo SM, Disney MD. (2014) Sequence-based design of bioactive small molecules that target precursor microRNAs. Nat Chem Biol [Epub ahead of print]. [abstract][/fusion_text][/fusion_builder_column_inner][/fusion_builder_row_inner][/fusion_builder_column]Related Posts
Researchers create first whole-body single-cell atlas of an adult vertebrate
UAlbany Joins $10 Million Effort to Map RNA Modifications in the Human Body
Overlooked ‘off switch’ in lung tumors may explain why immunotherapy doesn’t work for everyone
Squids Edit RNA for Novel Protein Functions
New marker panel and web tool help define early human cell fates
Researchers Develop AI Tool to Map MicroRNA Binding Sites on Circular RNAs
“Raman Genome” for SARS-CoV-2: new Raman technology distinguishes viral variants by their molecular RNA architecture
Advanced paternal age has sex-specific effects on fetal brain gene expression
Exercise is good for us—but why?
Heart failure reshapes bone marrow to create inflammation-related immune memory
Overlooked DNA regions surrounding ‘microexons’ hold missing pieces of autism’s genetic puzzle
An anti-senescence gene may fight spinal disc deterioration
Scientists identify the neuroblastoma cells that signal poor outcomes
Urine test may improve bladder cancer diagnosis and guide treatment decisions
Tracing 700 million years of cell evolution
RNA-Seq reveals a new way the developing heart controls its growth
The Human RNome Project Consortium seeks to publish first-ever complete sequence of the body’s RNA
Unmasking “zombie cells” in aging tissue with an AI-powered barcode
RNA variant imaging for cancer diagnosis
Autism-risk mutations reveal two opposing patterns of brain gene activity
Stay Connected
Submit a Post to the Blog
Recent Posts
Subscribe to the RNA-Seq Blog
RNA-Seq Products & Services